Single- And Multiple-Ascending Dose Studies Of DS-2325a, A KLK5 Inhibitor For The Treatment Of Netherton Syndrome
July 2024
in “
Journal of Investigative Dermatology
”
Studysummary In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →